Clinical Trial Update: Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC [Phase 2]

View source ↗

Summary

Phase 2 randomized study assessing docetaxel with or without vandetanib in metastatic transitional cell carcinoma of the bladder; study completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Transitional Cell Carcinoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Vandetanib (vandetanib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Transitional Cell Carcinoma, Bladder Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-06-04